Pipradrol
Pipradrol (Meratran) is a piperidine-based CNS stimulant from the 1950s, historically used for fatigue, mild depression, obesity and cognitive decline in the elderly. It is the structural parent of methylphenidate's diphenyl class and is now a controlled substance with little modern use.
01 Overview
Pipradrol produces stimulation and mood elevation through catecholamine reuptake inhibition. It saw broad mid-century use before falling out of favour as abuse potential and better-studied alternatives emerged.
It is internationally scheduled (Schedule IV of the Convention on Psychotropic Substances) and is chemically the parent of related stimulants such as desoxypipradrol. Clinical evidence is largely historical.
02 Mechanism
Norepinephrine-dopamine reuptake inhibitor (diphenylmethyl-piperidine class) that raises synaptic catecholamines, producing prolonged mild stimulation.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Historical | 1–2.5 mg/day | Oral | Historical adult dosing, morning. |
| Historical common | 2.5–5 mg/day | Oral | Divided; long duration means late doses disturb sleep. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Stimulation / mood liftIncreased energy, alertness and mood in historical use. | n/a | Observational | |
| Anti-fatigueReduced fatigue, used in the elderly and convalescent. | n/a | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| InsomniaProlonged action readily disrupts sleep. | Mild | Common | Observational | |
| Anxiety / overstimulationAnxiety, tremor and agitation at higher doses. | Moderate | Uncommon | Observational | |
| Cardiovascular stimulationRaised heart rate and blood pressure. | Moderate | Uncommon | Observational |